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Summary
Background: Vasopressin stimulates cyst growth in autosomal dominant polycystic kidney disease (ADPKD) and is a key
therapeutic target. Evaluation of high water intake as an alternative to pharmacological vasopressin blockade is supported
by patients. However feasibility, safety and adherence-promoting strategies required to deliver this remain unknown.
Aims: Assess the feasibility of a definitive randomized high water intake trial in ADPKD.
Methods: In this prospective open-label randomized trial, adult ADPKD patients with eGFR  20 ml/min/1.73 m2 were
randomized to prescribed high water (HW) intake targeting urine osmolality (UOsm) 270 mOsm/kg, or ad libitum (AW) in-
take (UOsm >300 mOsm/kg). Self-management strategies including home-monitoring of urine-specific gravity (USG) were
employed to promote adherence.
Results: We enrolled 42 participants, baseline median eGFR (HW 68.4 [interquartile range (IQR) 35.9–107.2] vs. AW 75.8 [IQR 59.0–
111.0 ml/min/1.73 m2, P¼ 0.22) and UOsm (HW 353 [IQR 190–438] vs. AW 350 [IQR 240–452] mOsm/kg, P¼ 0.71) were similar be-
tween groups. After 8 weeks, 67% in the HW vs. 24% in AW group achieved UOsm270 mOsm/kg, P¼ 0.001. HW group achieved
lower UOsm (194 [IQR 190–438] vs. 379 [IQR 235–503] mOsm/kg, P¼ 0.01) and higher urine volumes (3155 [IQR 2270–4295] vs. 1920
[IQR 1670–2960] ml/day, P¼ 0.02). Two cases of hyponatraemia occurred in HW group. No acute GFR effects were detected. In
total 79% (519/672) of USG were submitted and 90% (468/519) were within target. Overall, 17% withdrew during the study.
Conclusion: DRINK demonstrated successful recruitment and adherence leading to separation between treatment arms in
primary outcomes. These findings suggest a definitive trial assessing the impact of high water on kidney disease progres-
sion in ADPKD is feasible.
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Introduction
Autosomal dominant polycystic kidney disease (ADPKD) is the
commonest inherited kidney disorder, affecting 12 million peo-
ple globally.1 Continued cyst growth compresses the surround-
ing kidney parenchyma causing hypertension and kidney
function decline,2 with over 70% developing end stage kidney
disease by the sixth decade of life.3
Current treatment options for ADPKD are limited. Rigorous
blood pressure control targeting the renin angiotensin system
slows total kidney volume (TKV) growth but has no effect on
kidney function decline.4,5 Advancing knowledge of signalling
pathways implicated in cyst growth and disease progression
identified several potential therapies including somatostatin
analogues, mammalian target of rapamycin inhibitors and
metformin.6,7
The greatest advance has come from the recognition that
vasopressin modulates cystogenesis. It binds to V2 receptors in
the distal nephron and upregulates intracellular cyclic adeno-
sine monophosphate production resulting in disrupted tubulo-
genesis, excessive epithelial proliferation and secretion,
culminating in cyst formation and growth.8–10 This understand-
ing has led to licencing of the vasopressin receptor antagonist
tolvaptan for ADPKD.11,12 However, Tolvaptan access is limited
through cost, geographic location and considerable side effect
burden, restricting its use to more advanced disease.3
Vasopressin plays a pivotal role in osmoregulation.13 and
reducing its release by maintaining high water intake (HWI) is a
viable alternative to tolvaptan, with the additional benefit of
being a widely accessible affordable therapy commenced in
early disease given the favourable risk-benefit balance.14,15
Previous studies have indicated that HWI and solute restriction
successfully lower urine osmolality (UOsm) and copeptin in
ADPKD patients over the short-term.16–18 However, none of
these studies were performed in the tolvaptan-era. Furthermore
a non-randomized study paradoxically found a possible detri-
mental effect of HWI on kidney function.19 Demonstrating bio-
logical feasibility through measuring vasopressin is a challenge
given its short half-life and concerns persist over reliability of
copeptin, a surrogate for vasopressin, in CKD.13,15,20–22
Alternative surrogates of vasopressin suppression include
plasma and UOsm. UOsm is highly correlated with copeptin and
vasopressin concentrations in ADPKD,23 its ease of measure-
ment makes it an ideal surrogate for large-scale trials.
Although, a small intermediate-endpoint trial is currently
underway to assess the effect of hydration on TKV24 controver-
sies regarding use of TKV as a surrogate for renal endpoints re-
main.25 Therefore questions persist over feasibility of HWI trials
in the presence of Tolvaptan access, safety of the intervention
and the optimal renal outcome selection which is influenced by
acute GFR effects.
We conducted a randomized controlled trial of high (HW) vs.
ad libitum (AW) water intake in patients with ADPKD to assess
the feasibility and inform the design of a large definitive trial in
a developed healthcare setting with access to tolvaptan.
Materials and methods
Study design and participants
In this prospective, single-centre, open-label, randomized con-
trolled Phase 2 trial, the objective was to determine feasibility of
a definitive HWI trial. The study was co-produced by the PKD
Charity and Patient Led Research Hub,26 and the design and
protocol have been reported previously.27
Participants were recruited from the Renal Genetics clinic at
Addenbrooke’s Hospital, Cambridge. The trial was advertised
nationally via PKD Charity and RaDaR (National Registry of Rare
Kidney Diseases) websites. We recruited subjects aged 16 years
or over, with ADPKD and an estimated GFR 20 ml/min/1.73 m2,
able to self-monitor urine-specific gravity (USG). ADPKD
Diagnosis was confirmed using the modified Pei-Ravine crite-
ria,28 with supportive evidence of a pathogenic ADPKD mutation
if available. Exclusion criteria were; (i) advanced renal failure
(eGFR <20 ml/min/1.73 m2), (ii) fluid overload states or diuretics,
(iii) other renal diseases and (iv) participants taking tolvaptan
within 4-weeks of screening (Supplementary Table S1). All par-
ticipants provided written informed consent. The study was
approved by the East of England Essex Research Committee (16/
EE/0026).
Randomization and masking
Participants were randomized (1:1) to either HW or AW intake
groups using a sealed envelope system. The study was un-
blinded.
Procedures
HW group participants were given an individualized daily fluid
prescription derived from the free-water clearance formula
(Supplementary eTable S2a).27 The AW group was advised to
drink to thirst with a target UOsm 300 mOsm/Kg. At baseline,
both groups were guided through trial smartphone application
installation and given secure login details. They were provided
with Siemens Multistix GP indicator strips and shown how to
test their urine and read the USG. The HW group was asked to
maintain a USG  1.010 (consistent with vasopressin suppres-
sion) and those in the AW group were asked to maintain USG >
1.010. Participants tested USG twice weekly between 4 and 8
pm, and recorded results via the app. Fluid intake was then
titrated by participants according to USG using instructions
signposted through the app (Supplementary Table S2b). Results
could also be telephoned, emailed or texted.
Participants taking diuretics which could be stopped safely
underwent a 2-week washout prior to inclusion.
Study evaluations were performed at baseline, Weeks 2, 4
and 8 and included physical examination with fluid-balance as-
sessment (Supplementary Table S3). Blood pressure was
assessed using an automated device (DINAMAP Carescape).
Three measurements were taken after 5 min rest and the aver-
age of the second and third reported. Creatinine was measured
using the Siemens Advia_2400 autoanalyser. Estimated GFR was
calculated using the Chronic Kidney Disease Epidemiology
Collaboration (CKD-EPI) equation.29 Plasma and spot UOsm
were measured by the freezing point depression method
(Advanced Instruments Model_3320). Urine indicator strip test-
ing for proteinuria, haematuria and USG was performed using
Siemens Multistix GP indicator strips, read by Siemens CliniTek
Statusþauto-analyser. Patients underwent dietary review to en-
sure moderate solute intake (sodium <2 g/day and protein 0.75–
1 g/kg/day). Twenty-four-hour urine collections for osmolality
and volume were obtained. In exploratory analyses, serum
copeptin was analysed by the Department of Clinical Chemistry
at the Royal Victoria Infirmary, Newcastle.
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Outcomes
The primary outcomes were (i) the recruitment rate and poten-
tial, defined as the proportion of eligible participants enrolled
and (ii) the proportion of the HW group that achieved a UOsm
270 mOsm/kg at Week 8.
Secondary outcomes included demonstration of separation
in UOsm between treatment arms at Week 8, the proportion of
participants able to reliably self-monitor and report USG,
change in copeptin, determinations of acute changes in meas-
ured and estimated GFR between baseline and Week 4, and inci-
dence of adverse events.
Statistical analysis
Data from a previous RCT has shown that Tolvaptan resulted in
UOsm < 300 mOsm/kg in 81% vs. 17% (placebo).30 We consid-
ered that similar proportions would be required for a clinically
meaningful difference in kidney function decline rate. A min-
imum of 30 patients would yield 99% power at a two-sided
alpha of 0.05 to detect target UOsm in 85% of the HW group,
allowing for a 15% drop-out.
Categorical variables were reported as frequency (percent).
Continuous variables were expressed as mean 6 SD or median
(interquartile range [IQR]). We assessed the change in UOsm
over time using multi-level mixed effects models. In a basic
model the outcome variable was assessed using an interaction
term between visit number and treatment group as a fixed
effects regression coefficient, with a random intercept account-
ing for between-subject variations. Further models added the
following covariates to the fixed part of the model; age, gender,
and eGFR. The odds of maintaining a low USG (1.010) were
explored using logistic regression. Data were analysed by
intention-to-treat. All tests were two-sided with 0.05 signifi-
cance level. Analyses were performed using STATA-V.15
(College Station, TX).
Results
Between January 2017 and January 2018, 45% (42/93) of all eli-
gible participants were enrolled at an average rate of 3.5
patients per month (Figure 1). Actual patient accrual exceeded
this, but enrolment was limited by staffing capacity. Tolvaptan
prescribing was introduced at our centre during the second
study month in accordance with NICE guidelines.31 There was
some overlap in eligibility criteria between the study and
Tolvaptan; however, DRINK did not require evidence of rapid
disease progression and permitted the inclusion of lower eGFR
cut-off (Tolvaptan cut-off eGFR 30 ml/min/1.73 m2). Although
38% (35/93) were eligible for Tolvaptan, only 13% (12/93) com-
menced the drug. Forty-two participants were subsequently
randomized to the HW (n ¼ 21) or AW (n ¼ 21) group (Figure 2).
Thirty five participants completed the trial, with 7 (17%) with-
drawals during the study (HW 4/21, 19%; AW 3/21, 14%). One
participant (HW) was withdrawn due to a serious urinary tract
infection requiring hospitalization; the remaining six subjects
withdrew consent.
Baseline characteristics were similar between groups
(Table 1). In total 57% were female, 88% (37) were of White
British ethnicity and the mean age was 46 6 13 years. Both me-
dian spot (352 mOsm/kg IQR 202–452) and 24-h (319 mOsm/kg
IQR 251–420) UOsm were above the HW treatment target.
Median eGFR was 75.8 ml/min/1.73 m2 (IQR 46.5–107.5) and 81%
of patients had at least one risk factor for progression (hyper-
tension, microscopic haematuria, large kidney size).
In the HW group, mean fluid prescription at baseline was
3566 6 834 ml. UOsm 270mOsm/kg was achieved in 14/21
(67%) patients in the HW group and 5/21 (24%) in the AW group
at Week 8 (P ¼ 0.001). In a post hoc per-protocol analysis (exclud-
ing withdrawals) this increased to 82 vs. 26%, respectively.
The 8-week median spot UOsm was 194 (IQR 157–255)
mOsm/Kg for HW vs. 379 (IQR 235–503) for AW (P ¼ 0.01). Mean
difference from baseline to Week 8 in UOsm was 82 (SD 6158)
mOsm/kg (HW) vs. 47 (SD 6141) mOsm/kg (AW, P ¼ 0.01,
Figure 3A). In a mixed effects regression model randomization
to HW was associated with lower UOsm (ß 34.60 CI 67.26 to
1.93, P ¼ 0.04). In a multivariable model adjusting for age,
eGFR, and gender, only allocation to HW predicted a lower
UOsm (Supplementary Table S4). By Week 8, median 24-h urine
volume was higher in the HW group (3155 IQR 2270–4295 ml)
compared with the AW group (1920 IQR 1670–2960 ml), P ¼ 0.02.
Although effects of HWI on UOsm and volume appeared to be
greater at Week 2, this was not statistically significant.
Median USG was consistently 1.010 in the HW group and
1.015 in the AW group (P ¼ 0.0031, Figure 3E). In the logistic re-
gression model randomization to HW was associated with
lower USG over time (b 0.20, 95% CI 0.31 to 0.08, P ¼ 0.001).
Increasing median spot UOsm correlated with higher USG cat-
egory (P ¼ 0.0156); for USG 1.005 the median UOsm 174 (IQR 139–
210) compared with USG 1.030 where the median UOsm 462
(IQR 406–652) mOsm/kg (Supplementary Figure S2).
USG was performed and recorded for 79% (519/672) of time
points, and this was similar between groups (HW 75% vs. AW
79%, P ¼ 0.232). In total 70% (364/519) were submitted using the
app (Supplementary Table S5).
In the HW group, serum osmolality decreased from baseline
to Week 2 (290 6 8–286 6 8 mOsm/kg, P ¼ 0.09, Figure 3B), but
increased to 291 6 7 mOsm/kg by Week 8. Conversely in the AW
group serum osmolality increased by 2.5 6 4 mOsm/kg, P ¼ 0.02.
A small reduction in serum sodium concentration occurred
in the HW arm after 2 weeks (138 (IQR 137–140) mmol/l vs. 139
(IQR 139–140) mmol/l, P ¼ 0.02), although this was no longer sig-
nificantly by Week 8 (P ¼ 0.27, Figure 3C).
Baseline copeptin concentrations were low in both trial
arms. In the HW arm, copeptin decreased from baseline after 2
Figure 1. Cumulative number of participants enrolled each month from January
2017 until January 2018. Average recruitment was 3.5 participants per month.
Tolvaptan prescribing was introduced in our centre in March 2017. Participants
taking Tolvaptan were ineligible for the DRINK study.
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weeks (mean difference 0.2 6 0.5, P ¼ 0.0475, Figure 3D). In the
AW group copeptin increased from baseline to Week 8 (mean
difference 0.2 6 0.3, P ¼ 0.0093). Median copeptin was lower in
the HW group at Week 8 (HW 3.6 vs. AW 4.1, P ¼ 0.25).
Estimated GFR after 8 weeks did not differ between the HW
(79.3, 45.4–109.6 ml/min/1.73 m2) and AW groups (77.5, 50.1–
112.8 ml/min/1.73 m2, P ¼ 0.56). Change in eGFR from baseline
to Week 8 was similar between HW (0.7, 0.8 to 6.2 ml/min/1.73
m2) and AW (0.6, 5.0 to 3.6 ml/min/1.73 m2) groups (P ¼ 0.52,
Figure 3F). In a substudy including 8 HW participants, 51Cr-
EDTA measured GFR did not change from baseline (68, IQR 32–
75 ml/min) to 4 weeks (71, IQR 47–76 ml/min, P ¼ 0.95;
Supplementary Figure S1).
Other parameters including weight, blood pressure, potas-
sium, urea and creatinine levels, and 24-h urine solute excretion
showed no change (Table 2).
There was no significant difference in adverse events be-
tween treatment groups (Table 3). In total 63% (5/8) were
disease-related and included cysts infection, bleeding and pain.
One serious adverse event (renal cyst infection requiring
Figure 2. DRINK Study CONSORT flow diagram. A total of 50 patients were screened, 42 were randomized (HW ¼ 21, AW ¼ 21). Thirty-five participants completed the
trial. One participant was withdrawn by the chief investigator for clinical reasons, two participants (one from HW and one from AW group) withdrew after the Week 8
visit as they were unable to attend the final appointment due to work commitments, three participants (two from HW and one from the AW) were unable to attend fur-
ther appointments due to work/family commitments, and one participant in the AW group was uncontactable after the Week 2 visit.
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hospitalization) occurred in the HW group. There were two
cases of hyponatraemia (Na <132 mmol/l) in the HW group, in
patients with an eGFR of 28 and 57 ml/min/1.73 m2. Participants
received dietary reviews to ensure adequate salt intake and
fluid prescriptions were reduced with resolution in both cases.
Discussion
This randomized trial confirms the willingness of patients in a
developed healthcare setting with tolvaptan access to be ran-
domly assigned to HW or AW intake, at a rate of enrolment that
implies successful recruitment to a multi-centre large-scale trial
is feasible. A high degree of sustained adherence resulted in im-
portant differences between trial arms in UOsm, self-monitored
USG, plasma osmolality, sodium and urine volume. Our findings
are congruent with previous reports indicating that HWI in
ADPKD17,19 and unselected CKD32 could result in vasopressin
suppression, and suggest that it is plausible to observe a bio-
logical effect on kidney function in a definitive trial.
Baseline copeptin was lower in our trial population than
in other interventional studies,17,19 reflecting contemporary
specialist clinic advice to consume HWI exceeding 3 l/day.
The magnitude of copeptin reduction may therefore have
been smaller compared with populations where HWI is not
current practice. Further, copeptin was not a primary
Table 1. Baseline characteristics by treatment group. Values are reported as number (%), mean 6 SD, median (IQR)
Baseline demographic and clinical characteristics AW group (n ¼ 21) HW group (n ¼ 21)
Female 12 (57) 12 (57)
White British 18 (86) 18 (86)
Age (years) 44 6 12 49 6 13
Age at diagnosis (years) 31 6 14 32 6 15
Positive family history 18 (86) 18 (86)
Previous surgical intervention 0 (0) 1 (5)
Extra-renal manifestations 10 (48) 13 (62)
Hepatic cysts 10 (48) 12 (57)
Intracranial aneurysms 0 (0) 4 (19)
Cardiac valve abnormalities 0 (0) 2 (10)
Anti-hypertensives 10 (48) 17 (81)
Renin–angiotensin inhibition 8 (38) 13 (62)
Calcium channel blockers 6 (29) 10 (48)
Diuretics 3 (14) 2 (10)
Alpha blocker 2 (10) 4 (19)
Other 3 (14) 4 (19)
Comorbidities 16 (76) 17 (81)
Hypertension 11 (52) 16 (76)
Stroke 0 (0) 1 (5)
Liver disease 1 (5) 2 (10)
Ischaemic heart disease 0 (0) 0 (0)
Lung disease 2 (10) 2(10)
Migraine 2 (10) 1 (5)
Large kidney size 14 (67) 15 (71)
Physical parameters
Height centimetres 176.6 6 10.4 172.0 6 10.7
Weight kilograms 79.0 (67.1–88.6) 75.0 (66.5–84.0)
Body mass index 25 (21–31) 25 (22–31)
Systolic BP (mmHg) 134 6 19 139612
Diastolic BP (mmHg) 79 (74–87) 84 (76–91)
MAP (mmHg) 95 (91–104) 102 (97–107)
Blood biochemical parameters
Sodium (mmol/l) 139 (138–140) 139 (138–140)
Potassium (mmol/l) 4.2 (4.0–4.2) 4.5 (4.2–4.6)
Creatinine (mmol/l) 91 (62–115) 94 (66–149)
eGFR ml/min/1.73 m2 (CKD-EPI) 75.8 (59.0–111.0) 68.4 (35.9–107.2)
eGFR  60 ml/min/1.73 m2 15 (71) 11 (52)
Serum osmolality (mOsm/kg) 290 6 6 290 6 8
24-h urine parameters
Urine volume (ml/day) 2680 (2145–3480) 2403 (2042–3545)
UOsm (moSm/kg/day) 338 (259–409) 308 (229–437)
Urine solute excretion (mOsm) 757 (658–1068) 762 (672–957)
Spot urine parameters
UOsm (mOsm/kg) 350 (240–452) 353 (190–438)
Automated USG 1.015 (1.010–1.015) 1.010 (1.010–1.015)
Haematuria 7 (33) 4 (19)
Proteinuria 2 (10) 3 (14)
262 | QJM: An International Journal of Medicine, 2020, Vol. 113, No. 4
measure of separation in the present trial due to uncertainty
over whether it is a reliable surrogate for vasopressin in
CKD.21,33 Nevertheless, we observed only modest changes in
copeptin.
We report adherence to allocated treatment, sustained for
two months. Patients’ self-monitored USG, submitting data re-
motely with a high degree of completeness. As USG reliably
predicted measured UOsm, remotely monitored USG can be
incorporated in an efficient, pragmatic large trial design.
Although our trial was not powered to detect differences in
adverse events, two patients in the HWI arm developed hypona-
traemia. Given current recommendations1 of maintaining HWI
in ADPKD, along with previous reports of an unexpected associ-
ation with more rapid kidney function decline,19 there is an
Figure 3. Median spot UOsm was lower in the HW intake arm (A). By Week 2 there was a small decrease in serum osmolality (B) and sodium (C) in the HW group, but
this difference was not maintained at Week 8. Log copeptin (D) increased in the AW group, and although there was a decrease in the HW group by Week 2 this was not
maintained. Median USG was maintained at 1.010 in the HW group (E) and there were no acute effects on estimated glomerular filtration rate (F).
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urgent need to conduct a definitive trial to assess safety and
efficacy.
Our trial has several strengths, including its randomized na-
ture, assessment of pragmatic design components, use of effi-
cient self-monitoring approaches, patient engagement and
conduct in a setting with tolvaptan access. Further, the exclu-
sion of acute effects on measured GFR allows simple
approaches to renal function endpoints in future trials.
However, we demonstrated adherence over 8 weeks, long-term
sustainability is unknown and will require monitoring in a de-
finitive trial. Our study did not enrich the population for high
risk progressors34,35 and some uncertainty regarding replication
in higher risk populations remains. Finally, the study was not
powered to assess safety or efficacy.
Conclusion
Our findings suggest that a HWI trial in ADPKD is feasible, and
the adherence-promoting methods were effective and accept-
able. The risks of HWI in patients with ADPKD and reduced GFR
remain unknown and benefits unproven, yet HWI advice is rou-
tine. This study provides data of fundamental importance for
the design of a large-scale HWI trial. Several challenges remain
a definitive trial with primary kidney function outcomes neces-
sitates a reasonable sample size and therefore enrichment with
high risk progressors. This may be a particular challenge in
developed countries as tolvaptan adoption increases along with
the emergence of other competing studies.
Supplementary material
Supplementary material is available at QJMED online.
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26.Mader LB, Harris T, Kläger S, Wilkinson IB, Hiemstra TF.
Inverting the patient involvement paradigm: defining patient
led research. Res Involv Engagem 2018; 4:367.
27.El-Damanawi R, Lee M, Harris T, Mader LB, Bond S, Pavey H,
et al. Randomised controlled trial of high versus ad libitum
water intake in patients with autosomal dominant polycystic
kidney disease: rationale and design of the DRINK feasibility
trial. BMJ Open 2018; 8:e022859.
28.Pei Y, Obaji J, Dupuis A, Paterson AD, Magistroni R, Dicks E,
et al. Unified criteria for ultrasonographic diagnosis of
ADPKD. J Am Soc Nephrol 2009; 20:205–12.
29.Levey AS, Stevens LA, Schmid CH, Zhang YL, Castro AF,
Feldman HI, et al. A new equation to estimate glomerular fil-
tration rate. Ann Intern Med 2009; 150:604–12.
30.Devuyst O, Chapman AB, Gansevoort RT, Higashihara E,
Perrone RD, Torres VE, et al. Urine osmolality, response to tol-
vaptan, and outcome in autosomal dominant polycystic kid-
ney disease: results from the TEMPO 3: 4 trial. J Am Soc Nephrol
2017; 28:1592–602.
31.Tolvaptan for Treating Autosomal Dominant Polycystic Kidney
Disease j Guidance j NICE. NICE. https://www.nice.org.uk/guid
ance/ta358/chapter/1-Guidance (3 September 2019, date last
accessed).
32.Clark WF, Sontrop JM, Huang S-H, Gallo K, Moist L, House AA,
et al. Effect of coaching to increase water intake on kidney
function decline in adults with chronic kidney disease. JAMA
2018; 319:1810–70.
33.van Gastel MDA, Meijer E, Scheven LE, Struck J, Bakker SJL,
Gansevoort RT, et al. Modifiable factors associated with
copeptin concentration: a general population cohort. Am J
Kidney Dis 2015; 65:719–27.
34. Irazabal MV, Rangel LJ, Bergstralh EJ, Osborn SL, Harmon AJ,
Sundsbak JL, et al. Imaging classification of autosomal domin-
ant polycystic kidney disease: a simple model for selecting
patients for clinical trials. J Am Soc Nephrol 2015; 26:160–72.
35.Cornec-Le Gall E, Audrezet MP, Rousseau A, Hourmant M,
Renaudineau E, Charasse C, et al. The PROPKD score: a new al-
gorithm to predict renal survival in autosomal dominant
polycystic kidney disease. J Am Soc Nephrol 2016; 27:942–51.
R. El-Damanawi et al. | 265
